Core Viewpoint - Bid Pharma's stock price has experienced fluctuations, with a year-to-date increase of 49.79% but a recent decline of 7.01% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Bid Pharma achieved a revenue of 979 million yuan, representing a year-on-year growth of 20.67% [2] - The net profit attributable to shareholders for the same period was 120 million yuan, showing a year-on-year increase of 42.79% [2] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.64% to 3,493, while the average circulating shares per person increased by 8.27% to 12,377 shares [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Institutional Holdings - As of September 30, 2025, notable institutional shareholders include: - China Europe Medical Health Mixed A (003095) as the second-largest shareholder with 4.4532 million shares, an increase of 200,700 shares from the previous period [3] - China Europe Medical Innovation Stock A (006228) as a new fourth-largest shareholder with 2.0222 million shares [3] - Other new institutional shareholders include E Fund Value Growth Mixed (110010), ICBC Medical Health Stock (000831), and others [3] Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The company's revenue composition includes: - 43.26% from molecular building block heterocyclic compounds - 23.32% from molecular building block aromatic compounds - 16.36% from molecular building block aliphatic compounds - 10.57% from catalysts and ligands - 6.49% from life science reagents [1] Market Position - Bid Pharma is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing [1] - The company is associated with several concept sectors, including high dividend yield, financing, and small-cap stocks [1]

Core Insights - The total margin financing balance on the STAR Market decreased by 3.12 billion yuan compared to the previous trading day, while the margin short selling balance increased by 3.07 million yuan [1][2]. Financing Balance Summary - As of October 31, the total margin financing balance on the STAR Market reached 257.40 billion yuan, a decrease of 3.12 billion yuan from the previous trading day. The financing balance was 256.46 billion yuan, down by 3.12 billion yuan, while the short selling balance was 0.94 billion yuan, up by 3.07 million yuan [1]. - The stock with the highest financing balance was SMIC, with a latest balance of 14.49 billion yuan, followed by Cambrian and Haiguang Information with balances of 14.37 billion yuan and 8.50 billion yuan, respectively [1]. - Among the 256 stocks, 150 saw an increase in financing balance, while 330 experienced a decrease. The stocks with the largest increases in financing balance were Bid Medicine, Stone Technology, and Xingtou New Science, with increases of 27.59%, 24.09%, and 22.16%, respectively. Conversely, the largest decreases were seen in Tuojing Technology, Saiwei Microelectronics, and Aters, with declines of 18.80%, 15.43%, and 14.88% [1][2]. Short Selling Balance Summary - The stock with the highest short selling balance was Haiguang Information, with a latest balance of 0.49 billion yuan, followed by Cambrian and SMIC with balances of 0.37 billion yuan and 0.35 billion yuan, respectively [2]. - Among the stocks, 150 saw an increase in short selling balance, while 125 experienced a decrease. The stocks with the largest increases in short selling balance were Xidi Micro, Hangyu Technology, and United Imaging Healthcare, with increases of 846.74%, 760.59%, and 189.63%, respectively. The largest decreases were in Dize Pharmaceutical, Xinmai Medical, and Yingjixin, with declines of 67.22%, 59.95%, and 59.39% [2].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report emphasizes the ongoing progress of centralized procurement and medical insurance negotiations, highlighting investment opportunities in the pharmaceutical sector [5][6] - The report notes that the 2025 National Medical Insurance negotiations have commenced, with a focus on the commercialization potential of drugs included in the insurance list [6][19] - The pharmaceutical sector has shown resilience, with a 1.31% increase in October's fifth week, outperforming the CSI 300 index by 1.74 percentage points [7][22] Summary by Sections Section 1: Centralized Procurement and Medical Insurance Negotiations - The latest round of centralized procurement has been optimized, achieving a selection rate of 57% for the 11th batch, involving 55 products and 445 companies [5][15] - The 2025 medical insurance negotiations are expected to last 4-5 days, with 535 drug names passing the preliminary review for the basic medical insurance directory [6][19] Section 2: Market Performance - In the fifth week of October, the pharmaceutical sector rose by 1.31%, ranking 9th among 31 sub-industries [7][22] - The vaccine sector experienced the highest increase of 3.38%, while the medical consumables sector saw the largest decline of 1.98% [28] Section 3: Stock Recommendations - Monthly stock recommendations include companies such as Sanofi, Innovent Biologics, and WuXi Biologics [8] - Weekly stock recommendations feature companies like Kelun Pharmaceutical and Huadong Medicine [8]

Core Insights - Bid Pharma reported a revenue of 979 million yuan and a net profit attributable to shareholders of 120 million yuan for the first three quarters, representing year-on-year growth of 20.7% and 42.8% respectively [1] - The basic earnings per share reached 1.37 yuan, an increase of 45.7% compared to the previous year [1] - The company attributed its revenue growth primarily to an increase in market demand [1]

Financial Performance - The company's operating revenue for the third quarter reached ¥351,584,503.91, representing a year-on-year increase of 25.94%[4] - The total profit for the third quarter was ¥58,722,638.31, reflecting a significant increase of 53.98% compared to the same period last year[4] - The net profit attributable to shareholders for the third quarter was ¥46,327,956.87, up 44.71% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,295,471.69, showing a substantial increase of 79.40% compared to the previous year[4] - Total operating revenue for the first three quarters of 2025 reached ¥979,111,093.03, a 20.7% increase from ¥811,377,889.62 in the same period of 2024[22] - Net profit for the first three quarters of 2025 was ¥119,734,016.41, representing a 42.8% increase compared to ¥83,853,892.80 in the previous year[23] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥1.37, up from ¥0.94 in the same period of 2024[24] - The basic earnings per share for the third quarter were ¥0.54, reflecting an increase of 54.29% compared to the same period last year[5] - The company reported a total comprehensive income of ¥121,680,002.04 for the first three quarters of 2025, compared to ¥87,226,599.54 in the previous year[24] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥2,562,961,700.00, an increase of 5.99% from the end of the previous year[5] - As of September 30, 2025, the total assets of the company amounted to RMB 2,562,961,700, an increase from RMB 2,418,035,118.40 as of December 31, 2024, representing a growth of approximately 5.95%[16] - Total liabilities increased to ¥560,499,333.57, compared to ¥390,912,654.76 in the previous year, reflecting a significant rise in financial obligations[18] - Total equity attributable to shareholders decreased to ¥2,002,462,366.43 from ¥2,027,122,463.64 year-over-year[19] - The company's total current assets reached RMB 2,369,501,774.04, compared to RMB 2,208,723,169.25, which is an increase of about 7.29%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥8,732,704.38, which decreased by 91.32% year-on-year[4] - Cash flow from operating activities for the first three quarters of 2025 was ¥929,154,255.85, compared to ¥826,956,332.59 in the same period of 2024[25] - Operating cash inflow totaled $997,205,055.86, an increase of 12.1% from $889,986,877.02[26] - Operating cash outflow amounted to $988,472,351.48, up from $789,436,921.65, resulting in a net cash flow from operating activities of $8,732,704.38, down 91.3% from $100,549,955.37[26] - Cash inflow from investment activities reached $3,368,193,225.84, significantly higher than $360,254,145.57, while cash outflow was $3,486,621,789.06, leading to a net cash flow from investment activities of -$118,428,563.22[26] - Cash inflow from financing activities was $279,935,276.04, compared to $112,168,202.17, while cash outflow totaled $309,855,510.11, resulting in a net cash flow from financing activities of -$29,920,234.07[27] - The net increase in cash and cash equivalents was -$142,884,310.18, compared to -$386,156,614.74 in the previous period[27] - The ending balance of cash and cash equivalents stood at $953,736,388.07, up from $878,913,439.70[27] Shareholder Information - The company reported a total of 3,493 common shareholders at the end of the reporting period[12] - The company has a shareholding structure with significant stakes held by various investment partnerships, including 5,019,806 shares held by Zhoushan Xinxin Enterprise Management Partnership[14] - The company has a total of 4,730,172 shares repurchased, representing 5.20% of its total shares, which may indicate a strategy to enhance shareholder value[14] - The company has not reported any significant changes in the participation of major shareholders in margin financing or securities lending activities[14] Research and Development - Research and development expenses totaled ¥16,038,057.40 for the quarter, accounting for 4.56% of operating revenue, a decrease of 0.98 percentage points year-on-year[5] - Research and development expenses for the first three quarters of 2025 were ¥46,034,736.98, slightly up from ¥45,523,716.19 in the previous year[22] Financial Statements and Accounting - The company’s financial statements for the reporting period are unaudited, indicating a need for caution in interpreting the financial data[15] - The company will implement new accounting standards starting in 2025, which may affect the financial statements[28] Other Financial Metrics - Financial expenses recorded a loss of ¥7,098,512.41, contrasting with a gain of ¥5,325,990.16 in the same period of 2024[23] - The company received tax refunds of $40,429,228.34, compared to $37,423,828.32 in the previous period[26] - The company paid $134,615,488.48 in employee compensation, an increase from $127,648,964.92[26] - The company reported a decrease in tax payments to $38,142,548.69 from $53,293,563.62[26]

Group 1 - The core point of the article is that Bid Pharma reported significant growth in both revenue and net profit for the third quarter and the first three quarters of the year [1] Group 2 - For the third quarter, the company's revenue reached 352 million yuan, representing a year-on-year increase of 25.94% [1] - The net profit for the third quarter was 46.32 million yuan, showing a year-on-year growth of 44.71% [1] - For the first three quarters, the total revenue amounted to 979 million yuan, which is a year-on-year increase of 20.67% [1] - The net profit for the first three quarters was 120 million yuan, reflecting a year-on-year growth of 42.79% [1]

Core Viewpoint - Bid Pharma's stock increased by 5.03% to 80.86 CNY per share, with a total market capitalization of 7.349 billion CNY as of October 27 [1] Company Overview - Shanghai Bid Pharma Technology Co., Ltd. was established on April 27, 2007, and went public on October 11, 2022 [1] - The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - Main business revenue composition includes: - 43.26% from molecular building block heterocyclic compounds - 23.32% from molecular building block aromatic compounds - 16.36% from molecular building block aliphatic compounds - 10.57% from catalysts and ligands - 6.49% from life science reagents [1] Fund Holdings - Huashang Fund has a significant holding in Bid Pharma, with the Huashang Health Life Mixed Fund (001106) holding 62,400 shares, representing 2.22% of the fund's net value [2] - The fund has achieved a year-to-date return of 38.95%, ranking 1935 out of 8226 in its category [2] Fund Manager Information - The fund manager of Huashang Health Life Mixed Fund is Sun Wei, who has been in the position for 2 years and 298 days [3] - The total asset size of the fund is 7.139 billion CNY, with the best return during Sun Wei's tenure being 65.96% and the worst being -11.43% [3]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" [2] Core Views - The pharmaceutical industry is showing signs of marginal improvement, with Q3 performance expected to exceed expectations in high-growth areas [4][14] - The report suggests focusing on companies with strong Q3 performance, particularly in the CXO and life sciences upstream supply chain, medical device recovery, and innovative drugs [4][14] Summary by Sections Q3 Performance Highlights - Q3 performance is expected to be outstanding or exceed expectations, with recommendations to focus on companies such as Baipusais, Haoyuan Pharmaceutical, and Bid Pharmaceutical in the upstream research chain [4][14] - Medical devices are stabilizing or reversing in Q3, with suggested companies including Kefu Medical, Haitai New Light, and Maipu Medical [4][14] - Some traditional Chinese medicine companies are beginning to stabilize and are expected to benefit from the basic drug catalog catalyst, with recommendations for companies like Fangsheng Pharmaceutical and Kang Enbei [4][14] - API companies are stabilizing at the bottom, with CDMO business growth accelerating, recommending companies like Puluo Pharmaceutical and Tonghe Pharmaceutical [4][14] - The upstream pharmaceutical equipment is starting to stabilize, with recommendations for companies such as Sensong International and Chutian Technology [4][14] CXO and Life Sciences Upstream Supply Chain - Recommendations for globally influential CXO leading companies include WuXi AppTec, WuXi Biologics, and Kanglong Chemical [4][18] - For domestic clinical CRO leaders, companies like Tigermed and Pruvis are suggested [4][18] - Resource-based CXOs represented by safety evaluation and model animals include Zhaoyan New Drug and MediWest [4][18] - In the life sciences upstream supply chain, companies such as Baipusais and Haoyuan Pharmaceutical are recommended [4][18] High-end Medical Devices - The recovery of in-hospital procurement is driving business growth, with recommendations for companies like United Imaging and Kailing Medical [4][6][18] - The demand for consumer medical devices is gradually recovering, with suggested companies including Kefu Medical and Sanofi [4][6][18] - Companies benefiting from overseas orders recovery include Meihua Medical and Haitai New Light [4][6][18] - The market penetration rate of high-end medical device consumables continues to rise, with recommendations for companies like Maipu Medical and Xinhu Medical [4][6][18] Innovative Drugs - Focus on companies with scientific breakthroughs and forward-looking market space, including Innovent Biologics, Hengrui Medicine, and Junshi Biosciences [4][6][18] Market Performance - The pharmaceutical sector's return was 0.58% last week, ranking 25th among 31 first-level sub-industry indices [5][15] - The pharmaceutical industry index's current PE (TTM) is 30.35 times, which is relatively low compared to its historical average [19][24]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

Core Viewpoint - The current valuation of the pharmaceutical sector is at a low level, with public funds (excluding pharmaceutical funds) having low allocation to the sector. Considering the positive recovery of macroeconomic factors such as US Treasury rates and the driving effect of large categories and varieties on the industry, the growth of the pharmaceutical industry is expected to remain optimistic through 2025 [10]. Market Review - The CITIC Pharmaceutical Index rose by 0.56%, underperforming the CSI 300 Index by 2.69 percentage points, ranking 27th among CITIC's 30 primary industries [7]. - The top ten stocks by increase this week included Jianfa Zhixin, Te Yi Pharmaceutical, and Bi De Pharmaceutical, while the top ten stocks by decrease included Tuo Jing Life, Xin Nuo Wei, and Shu Tai Shen [7]. Overall View and Investment Themes - The pharmaceutical sector is expected to see a blooming of investment opportunities, particularly in innovative drugs, medical devices, and the innovative chain (CXO + life science services) [10]. - The innovative drug sector is transitioning from quantity logic to quality logic, emphasizing the importance of products that can ultimately generate profits [10]. - The medical device market is witnessing a recovery in bidding volumes, with a focus on home medical devices and orthopedic procurement [10]. - The innovative chain is expected to see a rebound in domestic financing, with a long-term trend towards high growth in the CXO sector [10]. - The pharmaceutical industry is anticipated to enter a new growth cycle, particularly in the specialty raw materials sector, which is currently at a near ten-year low in valuation [10]. Chromatography Industry Focus - Chromatography technology is crucial for the separation and analysis of components in various fields, especially in biopharmaceuticals, where it plays a key role throughout the drug development process [16][19]. - The global biopharmaceutical market is projected to grow from approximately $503 billion in 2023 to $892 billion by 2028, with a compound annual growth rate (CAGR) of 9.5%-12.5% [24]. - The Chinese biopharmaceutical market is also expanding rapidly, with a projected growth from ¥262.2 billion in 2018 to ¥534.8 billion in 2024, reflecting a CAGR of 12.61% [29]. Market Size and Growth - The global chromatography consumables market is expected to grow from $6.9 billion in 2023 to $9 billion by 2026, with a CAGR of 9.26% [37]. - The Chinese chromatography consumables market is projected to grow from ¥11.2 billion in 2023 to over ¥20.3 billion by 2026, with a CAGR of 21.92% [37]. - The global small molecule liquid chromatography market is expected to increase from $3.6 billion in 2021 to $7.7 billion by 2026, with a CAGR of 16.7% [30]. Domestic Industry Dynamics - Domestic chromatography companies are making significant strides in key areas such as chromatography media and industrial chromatography systems, accelerating the process of domestic substitution [44]. - The domestic chromatography media market is currently dominated by foreign companies, but advancements in domestic technology are enhancing competitiveness [44]. - The demand for chromatography products is driven by the need for cost-effective and reliable purification materials in biopharmaceutical production, where purification processes account for a significant portion of production costs [43].